Cosentyx and Tenosynovitis - a phase IV clinical study of FDA data

Summary:

Tenosynovitis is reported as a side effect among people who take Cosentyx (secukinumab), especially for people who are female, 40-49 old, have been taking the drug for 1 - 6 months also take Otezla, and have Psoriatic arthropathy.

The phase IV clinical study analyzes which people have Tenosynovitis when taking Cosentyx. It is created by eHealthMe based on reports of 187,010 people who have side effects when taking Cosentyx from the FDA, and is updated regularly.

What is Cosentyx?

Cosentyx has active ingredients of secukinumab. It is often used in psoriatic arthritis. eHealthMe is studying from 187,247 Cosentyx users. Check the latest studies of Cosentyx.

What is Tenosynovitis?

Tenosynovitis (inflammation of the fluid-filled sheath (called the synovium) that surrounds a tendon) is found to be associated with 453 drugs and 490 conditions by eHealthMe. Check the latest studies of Tenosynovitis.

On Jul, 31, 2026

187,010 people reported to have side effects when taking Cosentyx.
Among them, 436 people (0.23%) have Tenosynovitis.

Among these 436 people:

* Approximation only. Some reports may have incomplete information.

Do you take Cosentyx and have Tenosynovitis?

- Check whether Tenosynovitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cosentyx:

Cosentyx (187,247 reports)

Tenosynovitis treatments and more:

Tenosynovitis (4,673 reports)

How severe was Tenosynovitis and when was it recovered:

Tenosynovitis in Cosentyx

Expand to all the drugs that have ingredients of secukinumab:

Tenosynovitis and drugs with ingredients of secukinumab

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cosentyx:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Tenosynovitis:

Tenosynovitis (453 drugs)

Browse all the conditions that are associated with Tenosynovitis:

Tenosynovitis (490 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on secukinumab (the active ingredients of Cosentyx) and Cosentyx (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.